What are the underwriting syndicate, fees, and any lock‑up or lock‑in provisions attached to this offering?
Answer
The excerpt you shared about Assembly Biosciences’ $175 million equity financing does not contain the following details:
| Item | Information in the excerpt |
|---|---|
| Underwriting syndicate | Not listed |
| Underwriting fees / discount | Not disclosed |
| Lock‑up or lock‑in provisions | Not mentioned |
These elements are typically included in the “underwriting agreement” section of a company’s full press release or the related SEC filing (e.g., Form S‑1, Form 8‑K, or a prospectus supplement). To obtain the specific information you’re looking for, you can:
Locate the complete press release – The full Assembly Biosciences announcement (often posted on the company’s investor‑relations website or on GlobeNewswire) usually lists the lead underwriters, the full syndicate, the underwriting discount or commission, and any lock‑up periods for existing shareholders or insiders.
Review the SEC filing – The company’s filing with the SEC that accompanies the offering (e.g., a Form S‑1 or a Form 8‑K “Entry into a Material Definitive Agreement”) will contain a detailed “Underwriting” section, specifying:
- The names of the lead and participating underwriters.
- The total underwriting discount, commission, and any other fees.
- Any lock‑up or lock‑in agreements, including the duration (commonly 90 days for insiders, 180 days for certain shareholders, or other custom terms).
Contact Investor Relations – If the public documents do not provide the level of detail you need, you can request clarification directly from Assembly Biosciences’ Investor Relations team (contact information is usually listed at the bottom of the press release).
Typical structure (for reference)
When a company announces an underwritten offering, the relevant sections often read like this:
Underwriting Syndicate:
Lead underwriters: [Bank A], [Bank B]; Co‑underwriters: [Bank C], [Bank D], etc.Underwriting Discount/Commission:
Total discount: X% of the offering price (e.g., 2.5%); Commission: $Y million.Lock‑up/Lock‑in Provisions:
Standard lock‑up: 90‑day lock‑up on shares held by insiders;
Additional lock‑ins: May include a 180‑day lock‑up for certain large shareholders or a “sell‑off” restriction on the pre‑funded warrants.
Because the specific numbers and parties are not present in the snippet you posted, you’ll need to consult the full release or the SEC filing to capture the exact underwriting syndicate, fee structure, and any lock‑up terms attached to Assembly Biosciences’ $175 million offering.